**Question:** Which of the following statements about prasugrel is true as compared to clopidogrel?

A. Prasugrel has a faster onset of action than clopidogrel
B. Prasugrel requires activation by the liver enzyme CYP3A4
C. Prasugrel has a longer half-life than clopidogrel
D. Prasugrel has a higher potency than clopidogrel

**Core Concept:**
Prasugrel and clopidogrel are both P2Y12 receptor inhibitors, which are used for preventing platelet aggregation in patients with acute coronary syndromes (ACS). They are part of a group of drugs called thienopyridines. Prasugrel and clopidogrel differ in their pharmacokinetic and pharmacodynamic properties.

**Why the Correct Answer is Right:**
Prasugrel has a faster onset of action than clopidogrel because it is a prodrug that requires no liver activation. Prasugrel is activated directly into its active form (E5) upon reaching the bloodstream, unlike clopidogrel, which is a prodrug that requires activation by the liver enzyme CYP3A4. This means prasugrel starts working more quickly than clopidogrel.

**Why Each Wrong Option is Incorrect:**
A) Prasugrel has a slower onset of action than clopidogrel, which is incorrect.
B) Prasugrel is activated directly in the bloodstream, not by the liver enzyme CYP3A4, making this statement wrong.
C) Prasugrel has a shorter half-life than clopidogrel, which is incorrect. In fact, prasugrel has a longer half-life than clopidogrel.
D) Prasugrel is less potent than clopidogrel, which is incorrect. Prasugrel is in fact more potent than clopidogrel.

**Clinical Pearl:**
Prasugrel and clopidogrel differ in their pharmacokinetic and pharmacodynamic properties, which influence their clinical efficacy and side effect profiles. Understanding these differences helps in selecting the appropriate antiplatelet agent for a patient based on their clinical presentation and risk profile.